Creyon Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Creyon General Information
Description
Developer of drugs designed to engineer RNA-based medicines and their components. The company creates proprietary, purpose-built datasets that inform powerful machine learning models, identifying the design rules and engineering principles for safe and effective OBMs, enabling the healthcare sector to save costs for new medicines.
Contact Information
Website
www.creyon.comCorporate Office
- 8 Davis Drive
- Suite 220
- Durham, NC 27709
- United States
Corporate Office
- 8 Davis Drive
- Suite 220
- Durham, NC 27709
- United States
Creyon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 16-Apr-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 08-Mar-2022 | Completed | Generating Revenue | |||
| 1. Seed Round | 01-Mar-2020 | $5.5M | $5.5M | Completed | Startup |
Creyon Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed-2 | ||||||||
| Seed-1 | 10,998,308 | $0.000010 | $0.47 | $0.47 | 1x | $0.47 | 20.25% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Creyon Patents
Creyon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026080452-A1 | Fluorosulfonyl phosphoramidate (fsp) backbone modification and uses thereof | Pending | 07-Oct-2024 | ||
| US-20260226477-A1 | Transferrin receptor (tfr) aptamers and use thereof | Pending | 03-Jul-2024 | ||
| WO-2026011165-A1 | Transferrin receptor (tfr) aptamers and use thereof | Pending | 03-Jul-2024 | ||
| US-20250384958-A1 | Dose-response model for accurate detection and quantification of transcriptome-wide gene knockdown for oligonucleotide-based medicines | Pending | 24-May-2024 | ||
| WO-2024226802-A2 | Compositions and methods for allele specific modulation of tnpo2 expression | Inactive | 26-Apr-2023 | C12N15/113 |
Creyon Signals
Creyon Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lilly USA | Corporation | Minority | ||
| Tenmile | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| DCVC Bio | Venture Capital | Minority |
Creyon FAQs
-
When was Creyon founded?
Creyon was founded in 2019.
-
Where is Creyon headquartered?
Creyon is headquartered in Durham, NC.
-
What is the size of Creyon?
Creyon has 46 total employees.
-
What industry is Creyon in?
Creyon’s primary industry is Drug Discovery.
-
Is Creyon a private or public company?
Creyon is a Private company.
-
What is Creyon’s current revenue?
The current revenue for Creyon is .
-
How much funding has Creyon raised over time?
Creyon has raised $45.5M.
-
Who are Creyon’s investors?
Lilly USA, Tenmile, Alexandria Venture Investments, Casdin Capital, and DCVC Bio are 5 of 7 investors who have invested in Creyon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process